Hyperlipidemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hyperlipidemia. 253 active patents protecting 5 drugs from 5+ originators. First major cliff: 2029. Daily refresh.

5
Approved drugs
253
Active US patents
58/100
Avg vulnerability
—
Annual revenue covered

Originators in Hyperlipidemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Amarin Pharms 122 patents Fresenius Kabi 116 patents Merck & Co. 8 patents Idorsia 6 patents Salix 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hyperlipidemia. Each bar = one year. Y-axis scaled to peak year (72 patents).

4
27
1
29
72
30
1
31
9
32
55
33
1
35
10
36
31
37
24
38
15
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vascepa
ICOSAPENT ETHYL
 Amarin Pharms 122 50 — 2027-05-31
Unithroid
LEVOTHYROXINE SODIUM
 Fresenius Kabi 116 51 — 2031-08-06
Zetia
EZETIMIBE
 Merck & Co. 8 63 — 2033-05-01
Tryvio
APROCITENTAN
 Idorsia 6 63 — 2029-09-21
Tricor (Micronized)
FENOFIBRATE
 Salix 1 62 — 2033-05-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8324232 Tryvio method of use 81 2029-09-21
11174247 Tryvio method of use 75 2037-11-06
11787782 Tryvio method of use 75 2038-03-02
11680058 Tryvio method of use 75 2038-07-26
11241382 Unithroid method of use 70 2039-09-17
11241382 Unithroid method of use 70 2039-09-17
11241382 Unithroid method of use 70 2039-09-17
11241382 Unithroid method of use 70 2039-09-17
11241382 Unithroid method of use 70 2039-09-17
11241382 Unithroid method of use 70 2039-09-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10919881 Tryvio composition of matter 17 2038-02-26
8298554 Vascepa formulation 31 2030-04-29
8298554 Vascepa formulation 36 2030-04-29
10537538 Unithroid formulation 42 2037-02-28
11096913 Unithroid formulation 42 2037-02-28
11096913 Unithroid formulation 42 2037-02-28
11096913 Unithroid formulation 42 2037-02-28
11096913 Unithroid formulation 42 2037-02-28
10537538 Unithroid formulation 42 2037-02-28
10537538 Unithroid formulation 42 2037-02-28

Related